BLOG

Thursday, November 1, 2018

Falling rupee to boost pharma top lines, margins in Q2: India Ratings

However, drug firms focussed on domestic market would post muted growth in Q2FY19 on a year-on-year basis

from Companies https://ift.tt/2F30Ycq
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Omicron has cast a shadow of uncertainty on growth outlook: IndiGo CEO

However, the airline is stronger now when compared to situation in 2020 during the first wave of the pandemic, says Ronojoy Dutta from Com...